The Type 1 Diabetes (T1D) field is evolving.

Recognition of the presymptomatic stages in T1D is growing.^1-4 

The clinical benefits of early detection of T1D are being highlighted.^3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.^1,2

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.²

Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.¹

Polyp Gossip is a video podcast dedicated to exploring Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Hosted by two globally recognized rhinologists. The show delves into trending topics, latest advancements, and patient experiences. Each episode features esteemed guests, including experts and patients, offering valuable insights into the evolving world of CRSwNP.

Welcome to The Hematology Podcast, your source for the latest insights into hematology and rare blood disorders.

What links CRSwNP, asthma, and other comorbidities? In this episode, our experts unpack the unified airways concept and why it’s key to understanding Type 2 inflammation and optimizing patient care. Our experts discuss integrated care approaches and what they mean for clinical practice.

In this episode of Polyp Gossip, we explore the importance of a multidisciplinary approach in managing Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Join leading experts from rhinology and pulmonology as they discuss how collaboration across specialties can improve patient outcomes and optimize care pathways.

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

Think Fabry, think timely testing first.

Think Fabry, think regular profile-based assessments.